PROPHSY: Proteome in Pulmonary Hypertension Assay Score

Reference number 10746

Sectors: Healthcare, Medical Diagnostics

Industries: Biotechnology, Medical Diagnostics

A model score calculated from levels of circulating plasma proteins for the diagnosis, prognosis, and treatment optimisation of Pulmonary Arterial Hypertension.

Proposed use

  • Point of Care test: Pulmonary Arterial Hypertension diagnosis/prognosis – risk stratification
  • Pulmonary Arterial Hypertension treatment response and optimisation monitoring/evaluation

Problem addressed

Pulmonary arterial hypertension (PAH) is a rare condition that continues to be associated with a high morbidity and mortality burden. Because patients with PAH have very variable responses to standard therapies which is difficult to predict, as well as monitoring the effectiveness of such therapies. The N-terminal pro-brain natriuretic peptide (NT-proBNP), is a biomarker of cardiac origin already used to risk stratify patients with pulmonary arterial hypertension (PAH) but has its limitations, including poor sensitivity to early vascular pathology. The plasma proteome can inform prognosis beyond established factors in PAH and may provide a more sensitive and quicker measure of therapeutic response.

Technology overview

An aptamer-based assay targeting over 4000 proteins was used to measure plasma proteins in two idiopathic/heritable/drug-induced-PAH patient cohorts.

Discovery-validation survival analyses permitted identification of approximatively 30 proteins associated with PAH that could reproducibly inform prognosis independent of established prognostic factors NT-proBNP and 6-MWD.

From the 30 proteins a weighted combination score of 6 biomarker proteins (selected by LASSO) was developed and validated at baseline and follow-up study.

The value of this score permits, independently of established clinical targets, discrimination between:

  • Low/intermediate/high risk of PAH progression/death
  • Response to therapy
  • Development of PAH in at-risk individuals


  • Accessible point-of-care test for earlier diagnosis of PAH.
  • Non-invasive test
  • Easy to interpret single measurement
  • More sensitive measure of risk / therapeutic response / disease progression
  • Complements established clinical measures / risk algorithms
  • Reflects underlying pathobiology rather than late-stage heart failure

Development Stage

  • TRL 2/3
  • Model developed using SomaLogic SomaScan v4 data in UK PAH Cohort
  • Model validated in external cohort from Paris, France
  • 4/6 proteins validated by commercial ELISA measurements

Intellectual property information

A PCT Patent application has been published (WO2022/079448), covering the PROPHSY score and associated biomarkers. A national patent application has also been filed at the EPO.


Professor Martin R. Wilkins

Professor of Clinical Pharmacology
National Heart & Lung Institute, Faculty of Medicine

Visit personal site
Dr Christopher Rhodes

British Heart Foundation Senior Basic Science Fellow and Reader in Pulmonary Vascular Diseases
National Heart & Lung Institute, Faculty of Medicine

Visit personal site
Dr John Wharton

Honorary Senior Lecturer
National Heart & Lung Institute, Faculty of Medicine

Visit personal site

Contact us about this technology


Dr Amritha Nair

Industry Partnerships and Commercialisation Senior Executive, Faculty of Medicine

Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property; marketing of technologies primed for commercialisation and supporting commercialisation via licensing or spinouts. Amritha also supports researchers in their bids for access to translational funding. Amritha manages an extensive IP portfolio, mainly focussed on therapeutics and diagnostics. Prior roles include innovation consulting for small and medium enterprises and handling the drug development and start-up activities for a private equity backed life science development group in Houston, USA. Amritha has a PhD in Molecular and Human Genetics from Baylor College of Medicine, Houston, USA and a MSc in Human Genetics from Sri Ramachandra University, Chennai, India.

Contact Amritha

[email protected]

Related technologies

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.